Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Still listed by CMS but carries a termination date, so it is not valid for a current date of service.

Terminated with effect from 2021-03-31. This code was already terminated before the earliest quarterly file on record here, so the date it was first published is not recorded on this site. CMS still lists this code in the current quarterly file - it carries a termination date rather than being removed.